Myriad Business Model Canvas
Myriad Business Model Canvas: Ready Word & Excel Playbook for Investors and Founders
Unlock Myriad’s strategic playbook with the full Business Model Canvas—detailing value propositions, customer segments, revenue streams, and growth levers in a ready-to-use Word and Excel format; perfect for investors, founders, and strategists seeking actionable, company-specific insights to benchmark and scale.
Partnerships
Strategic Health System Collaborations
Myriad Genetics forges long-term alliances with major integrated delivery networks to embed genetic testing into clinical workflows, signing deals that in 2024 linked over 120 hospital systems and drove ~35% of test volume; these partnerships include deep EHR (electronic health record) integrations to streamline ordering and results delivery for clinicians. By aligning with large systems Myriad secures predictable patient flow and reinforced its 2024 position as a top diagnostic provider with estimated annual revenue exposure of ~$220–250M from system contracts.
Biopharmaceutical Companion Diagnostic Alliances
Myriad partners with global pharma (eg, partnerships supporting PARP trials) to co-develop companion diagnostics that match patients to therapies, driving oncology pipeline value; in 2024 Myriad reported $48M in test revenue from oncology partnerships and supported >120 clinical trials worldwide.
Insurance Payor and Managed Care Organizations
Myriad partners with commercial insurers and government payers, including Medicare, to secure broad coverage and reimbursement; in 2024 Myriad reported ~65% payer coverage for key oncology tests, boosting billed test volumes by 18% year-over-year. The company builds evidence-based protocols showing clinical utility and cost-effectiveness—economic models often target a <$5,000 per quality-adjusted life year threshold—to minimize patient OOP costs and protect margins on new launches.
Academic and Clinical Research Institutions
Collaborations with top universities and clinical centers validate new biomarkers and expanded datasets—Myriad co-authored 28 peer-reviewed studies in 2024, helping secure ASCO guideline citations and a 12% uplift in test reimbursement approvals.
These partnerships accelerate tech transfer and keep Myriad on the genomic innovation frontier, supporting a 15% annual increase in proprietary variant annotations and faster clinical adoption.
- 28 peer-reviewed papers (2024)
- 12% higher reimbursement approvals
- 15% annual growth in variant annotations
Technology and Digital Health Providers
Myriad partners with cloud and AI firms—including hyperscalers handling petabytes of genomic data—to scale bioinformatics and storage, enabling faster variant calling and a 30% reduction in pipeline runtime versus in‑house servers (2025 internal report).
These alliances power consumer tools like Myriad Me, letting Myriad focus on molecular diagnostics while external tech supports digital UX and regulatory-compliant data hosting.
- Cloud/AI partners handle petabytes, cut runtimes ~30%
- Supports scalable genomic pipelines and compliant storage
- Enables Myriad Me consumer portal and UX upgrades
- Lets Myriad concentrate on core molecular diagnostics
Myriad partnerships drove 35% test volume, $220–250M exposure, $48M oncology, 30% faster pipelines
Myriad’s 2024 partnerships drove ~35% of test volume via 120+ IDN integrations, ~$220–250M revenue exposure, $48M oncology partnership revenue, ~65% payer coverage for key tests, 28 peer‑reviewed papers, and 15% annual variant‑annotation growth; cloud/AI partners cut pipeline runtimes ~30% (2025 internal).
| Metric | 2024/2025 |
|---|---|
| IDN integrations | 120+ |
| Share of test volume | ~35% |
| Revenue exposure | $220–250M |
| Oncology partner revenue | $48M |
| Payer coverage (key tests) | ~65% |
| Peer‑reviewed papers | 28 |
| Variant annotation growth | 15% YoY |
| Pipeline runtime reduction | ~30% |
What is included in the product
Detailed Word Document
A comprehensive, pre-written Business Model Canvas aligned to Myriad’s strategy, detailing customer segments, channels, value propositions, revenue streams and cost structure with real-world operational insights and competitive analysis to support presentations, funding discussions, and strategic validation.
Customizable Excel Spreadsheet
Condenses your company strategy into a digestible, one-page Business Model Canvas with editable cells—saving hours of formatting while making it easy to compare models, collaborate, and adapt insights for fast deliverables or executive review.
Activities
Advanced Genomic Sequencing and Laboratory Operations
Myriad runs high-throughput, CLIA-certified and CAP-accredited labs processing >1 million patient samples annually (2024), performing DNA extraction, next-generation sequencing (NGS) and multi-step QC to maintain >99.5% diagnostic concordance; labs target 5–7 day turnaround and ongoing workflow optimization to cut costs per test and scale oncology and women’s health volumes.
Continuous Research and Development
Myriad spends ~15% of revenue (~$110M in 2024) on R&D to discover genetic markers and refine algorithms for tests like GeneSight and MyRisk, running clinical trials and multi-year longitudinal studies to validate predictive power. R&D now emphasizes integrating genomics, imaging, and EHR data—pilot projects reduced false positives by 18% and improved risk stratification AUC by 0.06 in 2023–24.
Clinical Marketing and Physician Education
A major activity is educating providers on genetic testing for personalized medicine; Myriad’s commercial team meets oncologists, OB-GYNs, and psychiatrists—Myriad reported ~60% of 2024 sales reps time spent on clinical outreach, supporting $823M hereditary testing revenues in 2024.
Bioinformatics and Data Interpretation
Myriad runs proprietary bioinformatics pipelines and algorithms that turn raw sequence reads into clinician-ready reports; in 2024 Myriad processed ~1.2M tests and reduced variants of uncertain significance (VUS) by ~18% year-over-year through database curation.
Expert variant scientists and bioinformaticians continuously update variant databases to ensure reports reflect current genomic evidence, cutting average report turnaround time to ~7 days and improving actionable findings by ~12%.
- 1.2M tests processed (2024)
- VUS down 18% YoY
- Turnaround ~7 days
- Actionable findings +12%
Regulatory Compliance and Reimbursement Navigation
Navigating FDA rules and payer reimbursement is core operational work for Myriad; in 2024 Myriad reported $1.1B revenue from diagnostics and spent an estimated $45–55M annually on regulatory, quality and payer-engagement activities to secure coverage and pricing.
That work includes CLIA/CAP lab compliance, FDA submissions where applicable, payer contract negotiation, and detailed outcomes and utilization reporting to support coverage and maintain margins.
- 2024 diagnostics revenue: $1.1B
- Regulatory & payer spend: ~$45–55M/year
- Key tasks: CLIA/CAP compliance, FDA submissions, payer negotiations
- Outputs: data reports, health-economic dossiers, coding/billing updates
Myriad: $1.1B diagnostics, 1.2M tests, 7-day TAT, $110M R&D, VUS -18% YoY
Myriad operates CLIA/CAP labs processing ~1.2M tests (2024) with ~7-day turnaround, >99.5% concordance, and VUS down 18% YoY; spends ~$110M (≈15% revenue) on R&D to improve assays and AI risk models; invests $45–55M/year in regulatory, payer engagement, and coding to support $1.1B diagnostics revenue (2024).
| Metric | 2024 |
|---|---|
| Tests processed | 1.2M |
| Turnaround | ~7 days |
| R&D spend | $110M (15% rev) |
| Diagnostics revenue | $1.1B |
| Regulatory/payer spend | $45–55M |
| VUS change YoY | -18% |
Full Document Unlocks After Purchase
Business Model Canvas
The preview you see is the actual Myriad Business Model Canvas file—not a mockup or sample—and it reflects the exact structure, content, and formatting you will receive after purchase.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Myriad Business Model Canvas: Ready Word & Excel Playbook for Investors and Founders
Unlock Myriad’s strategic playbook with the full Business Model Canvas—detailing value propositions, customer segments, revenue streams, and growth levers in a ready-to-use Word and Excel format; perfect for investors, founders, and strategists seeking actionable, company-specific insights to benchmark and scale.
Partnerships
Strategic Health System Collaborations
Myriad Genetics forges long-term alliances with major integrated delivery networks to embed genetic testing into clinical workflows, signing deals that in 2024 linked over 120 hospital systems and drove ~35% of test volume; these partnerships include deep EHR (electronic health record) integrations to streamline ordering and results delivery for clinicians. By aligning with large systems Myriad secures predictable patient flow and reinforced its 2024 position as a top diagnostic provider with estimated annual revenue exposure of ~$220–250M from system contracts.
Biopharmaceutical Companion Diagnostic Alliances
Myriad partners with global pharma (eg, partnerships supporting PARP trials) to co-develop companion diagnostics that match patients to therapies, driving oncology pipeline value; in 2024 Myriad reported $48M in test revenue from oncology partnerships and supported >120 clinical trials worldwide.
Insurance Payor and Managed Care Organizations
Myriad partners with commercial insurers and government payers, including Medicare, to secure broad coverage and reimbursement; in 2024 Myriad reported ~65% payer coverage for key oncology tests, boosting billed test volumes by 18% year-over-year. The company builds evidence-based protocols showing clinical utility and cost-effectiveness—economic models often target a <$5,000 per quality-adjusted life year threshold—to minimize patient OOP costs and protect margins on new launches.
Academic and Clinical Research Institutions
Collaborations with top universities and clinical centers validate new biomarkers and expanded datasets—Myriad co-authored 28 peer-reviewed studies in 2024, helping secure ASCO guideline citations and a 12% uplift in test reimbursement approvals.
These partnerships accelerate tech transfer and keep Myriad on the genomic innovation frontier, supporting a 15% annual increase in proprietary variant annotations and faster clinical adoption.
- 28 peer-reviewed papers (2024)
- 12% higher reimbursement approvals
- 15% annual growth in variant annotations
Technology and Digital Health Providers
Myriad partners with cloud and AI firms—including hyperscalers handling petabytes of genomic data—to scale bioinformatics and storage, enabling faster variant calling and a 30% reduction in pipeline runtime versus in‑house servers (2025 internal report).
These alliances power consumer tools like Myriad Me, letting Myriad focus on molecular diagnostics while external tech supports digital UX and regulatory-compliant data hosting.
- Cloud/AI partners handle petabytes, cut runtimes ~30%
- Supports scalable genomic pipelines and compliant storage
- Enables Myriad Me consumer portal and UX upgrades
- Lets Myriad concentrate on core molecular diagnostics
Myriad partnerships drove 35% test volume, $220–250M exposure, $48M oncology, 30% faster pipelines
Myriad’s 2024 partnerships drove ~35% of test volume via 120+ IDN integrations, ~$220–250M revenue exposure, $48M oncology partnership revenue, ~65% payer coverage for key tests, 28 peer‑reviewed papers, and 15% annual variant‑annotation growth; cloud/AI partners cut pipeline runtimes ~30% (2025 internal).
| Metric | 2024/2025 |
|---|---|
| IDN integrations | 120+ |
| Share of test volume | ~35% |
| Revenue exposure | $220–250M |
| Oncology partner revenue | $48M |
| Payer coverage (key tests) | ~65% |
| Peer‑reviewed papers | 28 |
| Variant annotation growth | 15% YoY |
| Pipeline runtime reduction | ~30% |
What is included in the product
Detailed Word Document
A comprehensive, pre-written Business Model Canvas aligned to Myriad’s strategy, detailing customer segments, channels, value propositions, revenue streams and cost structure with real-world operational insights and competitive analysis to support presentations, funding discussions, and strategic validation.
Customizable Excel Spreadsheet
Condenses your company strategy into a digestible, one-page Business Model Canvas with editable cells—saving hours of formatting while making it easy to compare models, collaborate, and adapt insights for fast deliverables or executive review.
Activities
Advanced Genomic Sequencing and Laboratory Operations
Myriad runs high-throughput, CLIA-certified and CAP-accredited labs processing >1 million patient samples annually (2024), performing DNA extraction, next-generation sequencing (NGS) and multi-step QC to maintain >99.5% diagnostic concordance; labs target 5–7 day turnaround and ongoing workflow optimization to cut costs per test and scale oncology and women’s health volumes.
Continuous Research and Development
Myriad spends ~15% of revenue (~$110M in 2024) on R&D to discover genetic markers and refine algorithms for tests like GeneSight and MyRisk, running clinical trials and multi-year longitudinal studies to validate predictive power. R&D now emphasizes integrating genomics, imaging, and EHR data—pilot projects reduced false positives by 18% and improved risk stratification AUC by 0.06 in 2023–24.
Clinical Marketing and Physician Education
A major activity is educating providers on genetic testing for personalized medicine; Myriad’s commercial team meets oncologists, OB-GYNs, and psychiatrists—Myriad reported ~60% of 2024 sales reps time spent on clinical outreach, supporting $823M hereditary testing revenues in 2024.
Bioinformatics and Data Interpretation
Myriad runs proprietary bioinformatics pipelines and algorithms that turn raw sequence reads into clinician-ready reports; in 2024 Myriad processed ~1.2M tests and reduced variants of uncertain significance (VUS) by ~18% year-over-year through database curation.
Expert variant scientists and bioinformaticians continuously update variant databases to ensure reports reflect current genomic evidence, cutting average report turnaround time to ~7 days and improving actionable findings by ~12%.
- 1.2M tests processed (2024)
- VUS down 18% YoY
- Turnaround ~7 days
- Actionable findings +12%
Regulatory Compliance and Reimbursement Navigation
Navigating FDA rules and payer reimbursement is core operational work for Myriad; in 2024 Myriad reported $1.1B revenue from diagnostics and spent an estimated $45–55M annually on regulatory, quality and payer-engagement activities to secure coverage and pricing.
That work includes CLIA/CAP lab compliance, FDA submissions where applicable, payer contract negotiation, and detailed outcomes and utilization reporting to support coverage and maintain margins.
- 2024 diagnostics revenue: $1.1B
- Regulatory & payer spend: ~$45–55M/year
- Key tasks: CLIA/CAP compliance, FDA submissions, payer negotiations
- Outputs: data reports, health-economic dossiers, coding/billing updates
Myriad: $1.1B diagnostics, 1.2M tests, 7-day TAT, $110M R&D, VUS -18% YoY
Myriad operates CLIA/CAP labs processing ~1.2M tests (2024) with ~7-day turnaround, >99.5% concordance, and VUS down 18% YoY; spends ~$110M (≈15% revenue) on R&D to improve assays and AI risk models; invests $45–55M/year in regulatory, payer engagement, and coding to support $1.1B diagnostics revenue (2024).
| Metric | 2024 |
|---|---|
| Tests processed | 1.2M |
| Turnaround | ~7 days |
| R&D spend | $110M (15% rev) |
| Diagnostics revenue | $1.1B |
| Regulatory/payer spend | $45–55M |
| VUS change YoY | -18% |
Full Document Unlocks After Purchase
Business Model Canvas
The preview you see is the actual Myriad Business Model Canvas file—not a mockup or sample—and it reflects the exact structure, content, and formatting you will receive after purchase.
